Excalipoint Therapeutics

News

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.